Drug news

Allergan to co market Levadex in USA

Read time: 1 mins

Last updated:17th Oct 2012

Published:17th Oct 2012

Source: Pharmawand

Upon FDA approval, Allergan will commit its existing U.S. sales force currently pushing BOTOX for Chronic Migraine to headache specialists with MAP Pharmaceuticals' field sales force targeting neurologists and pain specialists doubling the sales opportunity. Levadex for Acute Migraine patients and Botox for Chronic Migraine patients.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Late-breaking data show reliable performance of small-diameter defibrillation lead, the OmniaSecure.- Medtronic.

Medtronic plc announced that its investigational OmniaSecure defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals, in the global Lead Evaluation for Defibrillation and Reliability (LEADR) Pivotal Trial.

3 mins

Drug news

Elinzanetant significantly reduces frequency and severity of moderate to severe hot flashes associated with menopause.- Bayer

Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced frequency and severity of moderate to severe vasomotor symptoms (VMS; also known as hot flashes) associated with menopause compared to placebo.

1 min

Drug news

Once-a-week dosing, insulin efsitora alfa delivers A1C reduction and safety profile consistent with daily insulin

Eli Lilly and Company announced positive topline results from the QWINT-2 and QWINT-4 phase III clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections

3 min

See all news